Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Pharm-country symbols : Tevjf save search
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.35%
H: 0.0%
C: 0.0%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.52%
H: 3.73%
C: 1.87%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.09%
H: 0.0%
C: 0.0%
disease treatment collaboration teva deal
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
Published: 2023-09-06 (Crawled : 14:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.31%
H: 0.1%
C: -0.52%
austedo congress teva
Teva Presents Real-World Data for AUSTEDO® (deutetrabenazine) Tablets with 4-Week Patient Titration Kit at Psych Congress Elevate 2023
Published: 2023-06-02 (Crawled : 23:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.69%
H: 0.14%
C: -0.28%
austedo teva
U.S. Mental Health Access Program Expands Medicine Donation to Seven New States
Published: 2023-05-03 (Crawled : 11:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.34%
H: 1.13%
C: -0.34%
health program
Complete Response Letter Received for AVT02 Biologics License Application
Published: 2023-04-14 (Crawled : 08:00) - biospace.com/
ALVO | $13.5 0.75% 0.74% 190K
|
n/a
|
| O: -14.46%
H: 0.0%
C: -8.97%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -7.13%
H: 1.05%
C: -3.6%
avt02 license application response
Teva to Present New Data on Once-Daily AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets at the 2023 American Academy of Neurology Annual Meeting
Published: 2023-04-11 (Crawled : 14:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 1.28%
H: 0.58%
C: -0.63%
austedo meeting teva
Teva Reaches Agreement With Arkansas to Settle the State’s Price Fixing Claims
Published: 2022-10-07 (Crawled : 16:00) - biospace.com/
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
|
| O: -3.32%
H: 0.0%
C: 0.0%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: -2.08%
teva agreement
Teva Announces Largest-Ever Trial to Collect Information from Patients and Physicians About TD, its Impact and Progression Over Time, and Evaluate Treatment-Related Outcomes
Published: 2022-10-06 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.57%
H: 1.94%
C: -1.48%
impact teva trial
Aflibercept 8 mg Meets Primary Endpoints in Two Global Pivotal Trials for DME and wAMD, with a Vast Majority of Patients Maintained on 12- and 16-week Dosing Intervals
Published: 2022-09-08 (Crawled : 13:20) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.65%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: 15.18%
H: 4.65%
C: 3.18%
trials global
CONNECT1 Study Published in Journal of Allergy and Clinical Immunology: In Practice Evaluates the Potential of ProAir® Digihaler® (albuterol sulfate) Inhalation Powder and Digihaler System to Help Improve Asthma Management
Published: 2022-09-07 (Crawled : 14:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.11%
H: 2.06%
C: 1.26%
proair management system potential study
Teva to Present Latest Data on AJOVY® (fremanezumab-vfrm) Injection at the 2022 American Headache Society Annual Meeting
Published: 2022-06-09 (Crawled : 18:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.34%
H: 0.0%
C: -3.65%
ajovy injection
Teva Presents New Long-Term AUSTEDO® (deutetrabenazine) Tablets Data at 2022 American Psychiatric Association Annual Meeting
Published: 2022-05-23 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.94%
H: 0.93%
C: -1.29%
austedo
Teva Announces Settlement with Lupin Resolving AUSTEDO® (deutetrabenazine) Patent Dispute
Published: 2022-05-02 (Crawled : 13:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -4.15%
H: 1.23%
C: -0.23%
austedo patent
Press Release: Dupixent® (dupilumab) approved by European Commission for children aged 6 to 11 years with severe asthma with type 2 inflammation
Published: 2022-04-07 (Crawled : 08:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: 4.21%
H: 0.0%
C: -0.61%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 1.74%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.3%
H: 2.79%
C: 2.2%
dupixent children
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
Published: 2022-03-07 (Crawled : 18:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -1.21%
H: 2.37%
C: -0.54%
revlimid ces
Regeneron Presents Encouraging Phase 2 Results for High-dose Aflibercept 8 mg in Wet Age-related Macular Degeneration at Angiogenesis Meeting
Published: 2022-02-11 (Crawled : 15:30) - biospace.com/
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.59%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.85%
H: 0.0%
C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K
|
Health Technology
|
| O: -0.16%
H: 0.0%
C: 0.0%
phase 2 phase 2 results results macular
Teva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S.
Published: 2021-12-22 (Crawled : 22:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -0.96%
H: 2.0%
C: 1.21%
narcan nasal spray
Teva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.
Published: 2021-12-01 (Crawled : 14:00) - biospace.com/
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: -1.64%
H: 1.25%
C: -2.73%
authorized
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.